Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Kurosky SK, Davis KL, Galindo CM. Effect of combination vaccines on hepatitis B vaccine compliance in children in the United States. Pediatr Infect Dis J. 2017 Jul;36(7):e189-96. doi: 10.1097/INF.0000000000001548
Abeysinghe S, Margulis AV, Mauskopf J, Ainsworth C. Risk factors for RSV hospitalization in healthy preterm infants: a meta-analysis. Letter to the editor. Pediatr Infect Dis J. 2017 Jul;36(7):696. doi: 10.1097/INF.0000000000001559
Mauskopf J, Margulis AV, Samuel M, Lohr KN. Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J. 2016 Jul;35(7):e229-38. doi: 10.1097/INF.0000000000001163
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008 Jun;40(5):1407-10. doi: 10.1016/j.transproceed.2008.03.084